Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Disarib||BCL2 inhibitor 17||Disarib is a small molecule inhibitor of BCL2, which targets the BH1 domain of BCL2, thereby interfering with the interaction between BCL2 and BAK, and subsequently, leading to apoptosis (PMID: 28223017).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian carcinoma||not applicable||Disarib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Disarib treatment led to apoptotic induction and resulted in tumor regression in ovarian carcinoma xenograft models (PMID: 27693384).||27693384|
|Unknown unknown||breast adenocarcinoma||not applicable||Disarib||Preclinical||Actionable||In a preclinical study, Disarib treatment led to apoptotic induction and resulted in tumor regression in breast adenocarcinoma cell line mouse models (PMID: 27693384).||27693384|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|